Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
Public ClinicalTrials.gov record NCT00117598. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).
Study identification
- NCT ID
- NCT00117598
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 169 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2005 (Type not available)
- Primary completion
- Aug 2007 (Actual)
- Completion
- Jan 2011 (Actual)
- Last update posted
- Mar 30, 2015
2005 – 2011
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Little Rock | Arkansas | 72205 | — |
| Pfizer Investigational Site | Fountain Valley | California | 92708 | — |
| Pfizer Investigational Site | Los Angeles | California | 90024-2828 | — |
| Pfizer Investigational Site | New Milford | Connecticut | 06776 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20007 | — |
| Pfizer Investigational Site | Boca Raton | Florida | 33428 | — |
| Pfizer Investigational Site | Honolulu | Hawaii | 96813 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60612 | — |
| Pfizer Investigational Site | Morristown | New Jersey | 07960 | — |
| Pfizer Investigational Site | Buffalo | New York | 14263 | — |
| Pfizer Investigational Site | New York | New York | 10029-6574 | — |
| Pfizer Investigational Site | Rochester | New York | 14642-8668 | — |
| Pfizer Investigational Site | Portland | Oregon | 97227 | — |
| Pfizer Investigational Site | Upland | Pennsylvania | 19013 | — |
| Pfizer Investigational Site | Austin | Texas | 78705 | — |
| Pfizer Investigational Site | Grapevine | Texas | 76051 | — |
| Pfizer Investigational Site | Houston | Texas | 77030-4009 | — |
| Pfizer Investigational Site | Temple | Texas | 76508 | — |
| Pfizer Investigational Site | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00117598, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2015 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00117598 live on ClinicalTrials.gov.